Overview

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This research study is studying an investigational drug as a possible treatment for uterine cancer. The drug involved in this study is: -AZD1775
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
AstraZeneca
Treatments:
Adavosertib